That is very good news. 70% is a robust reduction in Lp(a).
A couple points I would add:
The article claimed:
"There are currently no approved therapies that lower Lp(a), said study author Stephen Nicholls, MBBS, PhD,"
This is not totally accurate. PCSK9-I, such as Repatha, significantly lowers Lp(a) and has been approved by the FDA for several years. There is nuance, because PCSK9-I was approved by the FDA for lowering LDL and the fact that it lowers Lp(a) is a side benefit. However, PCSK9-I typically lowers Lp(a) by 20% to 45%, so there is a need for something more robust, as the new therapy would bring.
I've been on Repatha for 4.5 years and it has lowered my Lp(a) by about 40%. Mine is still very high, so I'm looking forward to the new therapies on the horizon which achieve a more robust reduction. Also, the 40% reduction is the low point and it really depends on where I am in the injection cycle, which is twice per month and very easy to do. If I get my lipid test done near the eand of the two week cycle, the reduction is more like 25%.
The study linked is probably more than 5 years away from FDA approval, if all goes right. However, there is a powerful Lp(a) reducing therapy which should be approved by the FDA sometime in 2025, which lowers Lp(a) about 80%.
https://ir.ionis.com/news-releases/...ces-enrollment-completion-phase-3-lpa-horizon
They are also working towards getting approval for this drug specifically to slow the progression of aortic stenosis:
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis [Lp(a)FRONTIERS CAVS]
https://www.novartis.com/clinicaltrials/study/nct05646381
They are currently enrolling patients for their Phase II trial and there may be members here who want to consider applying for enrollment. They are looking for individuals with mild or moderate AS and with high Lp(a). The full inclusion and exclusion criteria is listed here:
https://www.novartis.com/clinicaltrials/study/nct05646381#trial-eligibility
